ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for NAMS

Stock NameNewAmsterdam Pharma Company N.V. Ordinary Shares
TickerNAMS(USD) NASDAQ
TYPECommon Stock
CountryUSA

Show aggregate NAMS holdings

News associated with NAMS

Biotech And Medtech Stocks Rally After-Hours Across Key Names
(RTTNews) - On September 12, several healthcare and biotech stocks experienced a surge in after-hours trading, marked by sharp price movements across the sector. From thrombectomy devices to AI-powered diagnostics and T-cell therapies, companies including Penumbra, Check-Cap, Ada - 2025-09-15 01:33:05
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 9.7% on Insider Selling
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) shares were down 9.7% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $24.60 and last traded at $24.38. Approximately 255,361 shares traded hands during mid-day trading, a decline of 71% from the average daily volume […] - 2025-09-10 02:25:12
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price […] - 2025-09-02 04:26:55
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Wells Fargo & Company
Research analysts at Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report issued on Monday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $45.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 78.64% from […] - 2025-08-27 02:30:44
Zurcher Kantonalbank Zurich Cantonalbank Grows Position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
Zurcher Kantonalbank Zurich Cantonalbank raised its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 130.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,990 shares of the company’s stock after acquiring an additional 3,390 shares […] - 2025-08-11 04:32:58
Arizona State Retirement System Buys Shares of 10,486 NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
Arizona State Retirement System purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 10,486 shares of the company’s stock, valued at approximately $215,000. Several other large investors have also recently added to or reduced their stakes in the […] - 2025-07-23 04:54:51
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Buy” from Analysts
Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a […] - 2025-07-14 05:38:50
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Citigroup
Stock analysts at Citigroup started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $42.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 130.77% from the stock’s current price. Other analysts […] - 2025-06-19 02:26:48
Cantor Fitzgerald Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)
Stock analysts at Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $42.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 115.27% from the company’s previous […] - 2025-06-06 04:30:47
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,288 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) by 6.0% during the fourth quarter, HoldingsChannel reports. The firm owned 253,571 shares of the company’s stock after buying an additional 14,288 shares during the period. UBS AM a distinct business unit of […] - 2025-06-02 05:32:58
28,517 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Bought by Lazard Asset Management LLC
Lazard Asset Management LLC acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,517 shares of the company’s stock, valued at approximately $732,000. Other institutional investors and hedge funds have […] - 2025-05-21 05:38:58
2,000 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by National Bank of Canada FI
National Bank of Canada FI purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000 shares of the company’s stock, valued at approximately $51,000. Other large investors have also recently modified […] - 2025-04-13 05:44:48
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33
Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year […] - 2025-04-08 02:33:05
Keybank National Association OH Purchases Shares of 9,983 NewAmsterdam Pharma (NASDAQ:NAMS)
Keybank National Association OH purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,983 shares of the company’s stock, valued at approximately $257,000. Other large investors also recently bought and sold […] - 2025-03-12 05:49:05
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Brokerages
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year […] - 2025-02-19 05:06:49

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) NAMS holdings

DateNumber of NAMS Shares HeldBase Market Value of NAMS SharesLocal Market Value of NAMS SharesChange in NAMS Shares HeldChange in NAMS Base ValueCurrent Price per NAMS Share HeldPrevious Price per NAMS Share Held
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NAMS by Blackrock for IE00BYXG2H39

Show aggregate share trades of NAMS

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-06BUY55832.48034.620 34.406USD 19,199 21.43
2025-10-03BUY1,30230.67031.810 31.696USD 41,268 21.38
2025-10-02BUY18630.70030.800 30.790USD 5,727 21.32
2025-09-30BUY37228.44028.870 28.827USD 10,724 21.24
2025-09-26BUY37228.50028.610 28.599USD 10,639 21.17
2025-09-25BUY37226.29027.120 27.037USD 10,058 21.14
2025-09-24SELL-2,36726.76027.210 27.165USD -64,300 21.11 Loss of -14,342 on sale
2025-09-18BUY19226.73026.750 26.748USD 5,136 21.07
2025-09-17BUY57924.49025.320 25.237USD 14,612 21.05
2025-09-11SELL-19326.60027.350 27.275USD -5,264 20.97 Loss of -1,218 on sale
2025-09-10BUY38626.90027.030 27.017USD 10,429 20.93
2025-09-05SELL-19327.00027.046 27.041USD -5,219 20.84 Loss of -1,197 on sale
2025-08-29SELL-57924.05024.350 24.320USD -14,081 20.75 Loss of -2,070 on sale
2025-08-27BUY38624.47025.030 24.974USD 9,640 20.70
2025-08-26SELL-19325.19025.450 25.424USD -4,907 20.67 Loss of -917 on sale
2025-08-25BUY19324.70025.490 25.411USD 4,904 20.65
2025-08-20SELL-76824.32024.540 24.518USD -18,830 20.60 Loss of -3,007 on sale
2025-08-18BUY38425.40025.901 25.851USD 9,927 20.55
2025-08-08SELL-38425.31025.850 25.796USD -9,906 20.40 Loss of -2,074 on sale
2025-08-05BUY19221.73022.390 22.324USD 4,286 20.35
2025-08-01SELL-57521.28022.010 21.937USD -12,614 20.33 Loss of -923 on sale
2025-07-30BUY76822.43023.590 23.474USD 18,028 20.31
2025-07-17SELL-38421.98022.100 22.088USD -8,482 20.13 Loss of -752 on sale
2025-07-11SELL-1,54421.54022.130 22.071USD -34,078 20.09 Loss of -3,060 on sale
2025-07-07BUY57919.46019.850 19.811USD 11,471 20.07
2025-07-02BUY10,61518.96019.130 19.113USD 202,884 20.08
2025-06-25BUY38618.33018.799 18.752USD 7,238 20.14
2025-06-20BUY2,33617.96019.010 18.905USD 44,162 20.19
2025-06-13BUY1,29620.21021.910 21.740USD 28,175 20.24
2025-06-11BUY36020.50022.001 21.851USD 7,866 20.23
2025-06-10BUY36221.84022.250 22.209USD 8,040 20.22
2025-06-04SELL-18119.39020.080 20.011USD -3,622 20.23 Profit of 40 on sale
2025-04-23BUY18117.27017.570 17.540USD 3,175 20.91
2025-04-10SELL-1,44014.90015.790 15.701USD -22,609 21.58 Profit of 8,463 on sale
2025-04-08SELL-18015.16016.650 16.501USD -2,970 21.77 Profit of 948 on sale
2025-04-07SELL-18015.86016.020 16.004USD -2,881 21.86 Profit of 1,054 on sale
2025-04-04SELL-90515.81018.000 17.781USD -16,092 21.96 Profit of 3,781 on sale
2025-04-01BUY74818.38020.450 20.243USD 15,142 22.08
2025-03-31SELL-54320.47022.060 21.901USD -11,892 22.11 Profit of 113 on sale
2025-03-21BUY10,53323.87024.200 24.167USD 254,551 22.01
2025-03-14SELL-2,33623.37024.000 23.937USD -55,917 21.84 Loss of -4,897 on sale
2025-03-07SELL-29223.80024.230 24.187USD -7,063 21.66 Loss of -738 on sale
2025-03-04SELL-14621.50022.170 22.103USD -3,227 21.58 Loss of -76 on sale
2025-02-25BUY29217.88018.398 18.346USD 5,357 21.82
2025-02-19SELL-14619.12020.220 20.110USD -2,936 22.24 Profit of 311 on sale
2025-02-13BUY43519.40019.550 19.535USD 8,498 22.60
2025-02-12BUY14519.37019.450 19.442USD 2,819 22.72
2025-02-11BUY58019.09019.435 19.400USD 11,252 22.87
2025-01-17BUY58023.55024.090 24.036USD 13,941 24.71
2025-01-16BUY58023.42024.000 23.942USD 13,886 24.89
2025-01-10SELL-29024.95025.920 25.823USD -7,489 25.69 Loss of -40 on sale
2025-01-08SELL-58025.55026.350 26.270USD -15,237 25.96 Loss of -180 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NAMS

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19137,3815,561174,14178.9%
2025-09-18234,64839,983330,40671.0%
2025-09-17222,32713,257253,32187.8%
2025-09-16176,6470242,97572.7%
2025-09-15235,61114398,80159.1%
2025-09-12421,07025,427640,98365.7%
2025-09-11369,06566,561618,31259.7%
2025-09-10409,30065,129611,11567.0%
2025-09-09388,34394,605587,67266.1%
2025-09-08685,81054,5451,066,20464.3%
2025-09-05330,7955,022966,09834.2%
2025-09-04199,84112,222294,97467.7%
2025-09-03304,02334,109542,46656.0%
2025-09-02187,2160238,62678.5%
2025-08-29219,3060336,69365.1%
2025-08-28158,2320489,34832.3%
2025-08-27151,7920323,85946.9%
2025-08-26259,95225,225750,17734.7%
2025-08-25140,8843,205207,63967.9%
2025-08-22173,02534,454279,95761.8%
2025-08-21124,8220366,77334.0%
2025-08-20117,0426,425177,42566.0%
2025-08-19260,03611,482338,09376.9%
2025-08-18334,04434,445413,30280.8%
2025-08-15458,49332,803636,64772.0%
2025-08-14232,50016,048280,78182.8%
2025-08-13215,53339,624262,07282.2%
2025-08-12413,93110,899553,32074.8%
2025-08-11260,5000328,59479.3%
2025-08-081,083,04835,4051,237,40587.5%
2025-08-07178,56840271,72965.7%
2025-08-06227,638197467,45448.7%
2025-08-05158,0020244,62364.6%
2025-08-0479,5850226,85735.1%
2025-08-0196,7660228,36742.4%
2025-07-31198,6980281,74870.5%
2025-07-30412,0793602,77868.4%
2025-07-29184,1630387,94747.5%
2025-07-28155,46317261,45659.5%
2025-07-25170,4777,601271,74962.7%
2025-07-24244,814829375,81165.1%
2025-07-23202,6030385,96052.5%
2025-07-22164,3900670,41324.5%
2025-07-21180,0670526,44434.2%
2025-07-18215,0520464,05846.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy